

14 March 2014 EMA/125456/2014 Veterinary Medicines Division

Monthly report on application procedures, guidelines and related documents for veterinary medicines

February 2014

This report, which is updated every month, provides current information related to the volume and evaluation of pre- and post-authorisation applications for medicinal products for veterinary use received by the European Medicines Agency (EMA) for the current and previous three years on:

- scientific-advice requests;
- applications for initial evaluations, variations, extensions and renewals concerning marketing authorisations (MAs);
- applications for initial evaluations, extensions, modifications and extrapolations for maximum residue limits (MRLs);
- arbitration and referral procedures;
- requests for classification of products as Minor Use/Minor Species (MUMS)/limited market.

In addition, the report includes a summary table of the opinions issued by the Committee for Medicinal Products for Veterinary Use (CVMP) in the current year, as well as a list of adopted guidelines and other public guidance documents.

The purpose is only to provide ongoing factual information. Commentaries and analysis are provided in the Agency's annual reports.




An agency of the European Union


Statistics on pre- and post-authorisation applications for medicinal products for veterinary use

Scientific-advice requests						
	2011	2012	2013	2014		
Submitted	26	28	40	6		
Advice given	24	29	34	9		






Initial evaluation of marketing-authorisation applications					
	2011	2012	2013	2014	
Full (submitted)	8	12	23	1	
Abridged/generics (submitted)	3	0	0	0	
Withdrawals	0	1	0	0	
Positive opinions	19	9	12	3	
Negative opinions	0	0	0	0	




Pre-authorisation: outcome of the evaluation of MA applications



Marketing authorisations					
	2011	2012	2013	2014	
Granted	24	8	13	2	
Withdrawals	1	3	3	0	
Not renewed	0	0	0	0	

Extensions — applications					
	2011	2012	2013	2014	
Submitted	7	8	5	1	
Withdrawals	0	1	0	1	
Positive opinions	4	10	9	1	
Negative opinions	0	0	0	0	

Variations — applications submitted					
	2011	2012	2013	2014	
Type-IA variations	120	104	175	25	
Type-IB variations	101	96	108	23	
Type-II variations	45	52	32	7	
Transfers	3	2	24	0	



Post-authorisation: variations and transfers submitted

Renewals – applications					
	2011	2012	2013	2014	
Submitted	14	10	16	2	
Positive opinions	12	10	14	4	
Negative opinions	0	0	0	0	


Establishment of MRLs for new substances — applications						
2011 2012 2013 2014						
Submitted	1	1	7	1		
Withdrawals	0	1	1	0		
Positive opinions ¹	4	1	4	0		
Negative opinions	0	0	0	0		

¹ Including opinions recommending the extension of the expiry date for provisional MRLs or definitive MRLs for substances with previously provisional MRLs.

Extensions/modifications/extrapolations of MRLs — applications						
2011 2012 2013 2014						
Submitted	13	5	6	1		
Withdrawals	2	0	0	0		
Positive opinions ²	12	8 (2)	8	0		
Negative opinions	0	0	0	0		


² Including opinions recommending the extension of the expiry date for provisional MRLs or definitive MRLs for substances with previously provisional MRLs. Re-examination of opinions are indicated in brackets.

Substances considered as not falling within the scope of Regulation (EC) No $470/2009 -$ requests						
	2011	2012	2013	2014		
Submitted	5	9	16	1		
Agreed	10	6	9	2		
Not agreed	0	1	2	0		
Scientific advice recommended	0	0	6	0		



MRL-related submissions


MUMS/limited-market classification — requests						
	2011	2012	2013	2014		
Positive with financial incentives	8	16	10	0		
Positive without financial incentives	10	4	10	0		
Negative	3	1	3	0		



Positive with financial incentives Positive without financial incentives Negative

Arbitrations and referrals					
	2011	2012	2013	2014	
Arbitrations and referrals submitted	12	12	10	2	
Opinions ³	10	11 (1)	13 (3)	1	

³ Re-examination of opinions in brackets.



Arbitrations and referrals submitted and opinions

CVMP opinions in 2014 on medicinal products for veterinary use

Positive opinions

	oduct nvented name NN	Marketing authorisation holder	Therapeutic areaTarget speciesSummary of indication	EMA/CVMP • Validation • Opinion • Active time • Clock stop	European Commission • Opinion received • Transmission to EC • Decision • Notification • Official Journal
•	Fungitraxx Itraconazole	Avimedical B.V	 Ornamental birds For the treatment of aspergillosis and candidiasis in companion birds. 	 07/11/2012 16/01/2014 210 225 	16/01/201412/02/2014
•	Equisolon Prednisolone	• LE VET B.V.	 Horse Alleviation of inflammatory and clinical parameters associated with recurrent airway obstruction (RAO) in horses, in combination with environmental control. 	 10/10/2012 16/01/2014 210 253 	• 16/01/2014
•	Parvoduk Live attenuated Muscovy duck parvovirus	• MERIAL	 Muscovy duck Active immunisation of ducks to prevent mortality⁴ and to reduce weight loss and lesions of duck parvovirosis and Derzsy's disease. 	 07/11/2012 13/02/2014 203 260 	• 13/02/2014

⁴ In absence of maternally derived antibodies.

CVMP opinions in 2014 on establishment of MRLs

Positive opinions

Product	Target species	EMA/CVMP	European Commission
Substance INN		 Validation Opinion Active time Clock stop 	 Opinion received Decision Notification Official Journal
•	•	•	•

Arbitrations and referrals in 2014

Ongoing procedures

 Type of procedure Referral under Article 35 of Directive 	Date • Clock start • CVMP opinion • 12/09/2012	 Product Product name INN Suanovil 20 and associated names, Captalin and associated names and
2001/82/EC		generic products thereof, including pending applicationsSpiramycin
Referral under Article 34 of Directive 2001/82/EC	• 10/10/2012	 Linco-Spectin 100 and its associated names Lincomycin, spectinomycin
 Referral under Article 34 of Directive 2001/82/EC 	• 07/11/2012	 Baytril 2.5% injectable, Baytril 5% injectable and Baytril 10% injectable and their associated names Enrofloxacin
Referral under Article 30(3) of Regulation 726/2004	• 10/01/2013	LidocaineLidocaine
 Referral under Article 35 of Directive 2001/82/EC 	• 10/04/2013	 All veterinary medicinal products containing altrenogest to be administered orally to pigs and horses Altrenogest
Referral under Article 35 of Directive 2001/82/EC	• 16/05/2013	 Baytril 2.5% injectable, Baytril 5% injectable, Baytril 10% injectable and associated names and related veterinary medicinal products authorised under Article 13 of Directive 2001/82/EC Enrofloxacin

Type of procedure	Date • Clock start • CVMP opinion	Product • Product name • INN
Referral under Article 35 of Directive 2001/82/EC	• 06/11/2013	 All veterinary medicinal products containing tylosin to be administered orally via feed or the drinking water to pigs Tylosin
 Referral under Article 33(4) of Directive 2001/82/EC 	16/05/201315/01/2014	 Norbonex 5-mg/ml pour-on solution for beef and dairy cattle Eprinomectin
 Referral under Article 33(4) Directive 2001/82/EC (under re-examination) 	16/05/201311/12/2013	 Fiprex CAT 52.5 mg spot-on solution for cats, Fiprex S 75 mg spot-on solution for dogs, Fiprex M 150 mg spot-on solution for dogs, Fiprex L 300 mg spot-on solution for dogs and Fiprex XL 412.5 mg spot-on solution for dogs Fipronil
 Referral under Article 13 of Regulation (EC) No. 1234/2008 	• 12/02/2014	Resflor solution injectableFlorfenicol, flunixin
 Referral under Article 13 of Regulation (EC) No. 1234/2008 	• 12/02/2014	 Ubrolexin intramammary suspension for lactating dairy cows Cephalexin, kanamycin

Guidelines and working documents in 2014

CVMP quality

Reference number	Document title	Status
EMA/CHMP/CVMP/QWP/70278/20 12-Rev.1	Guideline on process validation for finished products. Information and data to be provided in regulatory submissions.	Adopted January 2014 (End of consultation 31 October 2012)
EMA/CHMP/CVMP/QWP/441071/2 011	Guideline on stability testing for applications for variations to a marketing authorisation.	Adopted January 2014 (End of consultation 31 January 2012)
[Published on EMA website]	Revised Q&A on Limits for microbiological quality for premixes for medicated feeding stuffs which contain excipients of natural origin.	Adopted January 2014

CVMP efficacy

Reference number	Document title	Status
EMA/CVMP/EWP/513162/2013	Guideline on for the conduct of efficacy studies for non-steroidal	Adopted January 2014
	anti-inflammatory drugs (NSAID)	(End of consultation
	(Revised).	31 May 2013)

Antimicrobials

Reference number	Document title	Status
EMA/CVMP/AWP/119489/2012- Rev.1)	Reflection paper on the use of pleuromutilins in food-producing animals in the European Union: development of resistance and impact on human and animal health	Adopted February 2014
	(Revised).	

General

Reference number	Document title	Status
EMA/CVMP/VICH/758781/2013	Draft VICH GL53 on electronic exchange of documents: file format requirements – 6 months public consultation.	Adopted for consultation, February 2013. (End of consultation 20 July 2014)